Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs

H. Elizabeth Broome; Alice L. Yu; Mitch Diccianni; Bruce M. Camitta; Brett P. Monia; Nicholas M. Dean

doi:10.1016/S0145-2126(01)00118-7

Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs

H. Elizabeth Broome^*
, Alice L. Yu
, Mitch Diccianni
, Bruce M. Camitta
, Brett P. Monia
, Nicholas M. Dean

^*Corresponding author for this work

University of California at San Diego
Midwest Children’s Cancer Center
Ionis Pharmaceuticals

Research output: Contribution to journal › Journal Article › peer-review

30 Scopus citations

Abstract

We have examined the effects of antisense oligonucleotides to bcl-x on the survival and chemosensitivity of CEM cells, a T-acute lymphoblastic leukemia (T-ALL) cell line. Also, we have measured the levels of Bcl-2, Bcl-x, and Bax in 20 cases of T-ALL. By 18 h after the bcl-x antisense treatment, CEM cells showed over a 75% reduction in the levels of Bcl-xL protein and over 30% decreased viable cell counts compared with cells treated with the control oligonucleotide. The combination of bcl-x antisense plus either dexamethasone or doxorubicin showed either strong synergistic or additive killing of CEM cells, respectively. These findings indicate that bcl-x antisense has cytotoxic activity and increases chemotherapy-induced cell death in CEM cells, a model for T-ALL.

Original language	English
Pages (from-to)	311-316
Number of pages	6
Journal	Leukemia Research
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/S0145-2126(01)00118-7
State	Published - 2002
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antisense
Drug sensitivity
Glucocorticoid
T-ALL
bcl-2
bcl-x

Access to Document

10.1016/S0145-2126(01)00118-7

Cite this

@article{0c7dcf93aae2416b9211ea8a617d770f,

title = "Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs",

abstract = "We have examined the effects of antisense oligonucleotides to bcl-x on the survival and chemosensitivity of CEM cells, a T-acute lymphoblastic leukemia (T-ALL) cell line. Also, we have measured the levels of Bcl-2, Bcl-x, and Bax in 20 cases of T-ALL. By 18 h after the bcl-x antisense treatment, CEM cells showed over a 75\% reduction in the levels of Bcl-xL protein and over 30\% decreased viable cell counts compared with cells treated with the control oligonucleotide. The combination of bcl-x antisense plus either dexamethasone or doxorubicin showed either strong synergistic or additive killing of CEM cells, respectively. These findings indicate that bcl-x antisense has cytotoxic activity and increases chemotherapy-induced cell death in CEM cells, a model for T-ALL.",

keywords = "Antisense, Drug sensitivity, Glucocorticoid, T-ALL, bcl-2, bcl-x",

author = "Broome, \{H. Elizabeth\} and Yu, \{Alice L.\} and Mitch Diccianni and Camitta, \{Bruce M.\} and Monia, \{Brett P.\} and Dean, \{Nicholas M.\}",

year = "2002",

doi = "10.1016/S0145-2126(01)00118-7",

language = "英语",

volume = "26",

pages = "311--316",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs

AU - Broome, H. Elizabeth

AU - Yu, Alice L.

AU - Diccianni, Mitch

AU - Camitta, Bruce M.

AU - Monia, Brett P.

AU - Dean, Nicholas M.

PY - 2002

Y1 - 2002

N2 - We have examined the effects of antisense oligonucleotides to bcl-x on the survival and chemosensitivity of CEM cells, a T-acute lymphoblastic leukemia (T-ALL) cell line. Also, we have measured the levels of Bcl-2, Bcl-x, and Bax in 20 cases of T-ALL. By 18 h after the bcl-x antisense treatment, CEM cells showed over a 75% reduction in the levels of Bcl-xL protein and over 30% decreased viable cell counts compared with cells treated with the control oligonucleotide. The combination of bcl-x antisense plus either dexamethasone or doxorubicin showed either strong synergistic or additive killing of CEM cells, respectively. These findings indicate that bcl-x antisense has cytotoxic activity and increases chemotherapy-induced cell death in CEM cells, a model for T-ALL.

AB - We have examined the effects of antisense oligonucleotides to bcl-x on the survival and chemosensitivity of CEM cells, a T-acute lymphoblastic leukemia (T-ALL) cell line. Also, we have measured the levels of Bcl-2, Bcl-x, and Bax in 20 cases of T-ALL. By 18 h after the bcl-x antisense treatment, CEM cells showed over a 75% reduction in the levels of Bcl-xL protein and over 30% decreased viable cell counts compared with cells treated with the control oligonucleotide. The combination of bcl-x antisense plus either dexamethasone or doxorubicin showed either strong synergistic or additive killing of CEM cells, respectively. These findings indicate that bcl-x antisense has cytotoxic activity and increases chemotherapy-induced cell death in CEM cells, a model for T-ALL.

KW - Antisense

KW - Drug sensitivity

KW - Glucocorticoid

KW - T-ALL

KW - bcl-2

KW - bcl-x

UR - https://www.scopus.com/pages/publications/0036138556

U2 - 10.1016/S0145-2126(01)00118-7

DO - 10.1016/S0145-2126(01)00118-7

M3 - 文章

C2 - 11792421

AN - SCOPUS:0036138556

SN - 0145-2126

VL - 26

SP - 311

EP - 316

JO - Leukemia Research

JF - Leukemia Research

IS - 3

ER -

Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this